NCT01566773CompletedPhase 2
A Randomized, Double Blind (Test Products and Placebo), Chronic Dosing (14 Days), Four Period, Eight Treatment, Placebo-Controlled, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Six Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide, Open Label) as An Active Control
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Pearl Therapeutics, Inc.
- Enrollment
- 140
- Locations
- 1
- Primary Endpoint
- FEV1 AUC0-12
Study Overview
Brief Summary
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
Detailed Description
The primary objective of this study is to assess efficacy relative to placebo of GP MDI in subjects with moderate to severe chronic obstructive pulmonary disease (COPD) within the range of doses evaluated in this protocol. To this end, each dose of GP MDI will be compared to placebo with respect to the primary efficacy endpoint, FEV1 AUC0-12 relative to baseline.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed written informed consent
- •40 - 80 years of age
- •Clinical history of COPD with airflow limitation that is not fully reversible
- •Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods
- •Current/former smokers with at least a 10 pack-year history of cigarette smoking
- •A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70
- •A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of predicted normal values
- •Able to change COPD treatment as required by protocol
Exclusion Criteria
- •Women who are pregnant or lactating
- •Primary diagnosis of asthma
- •Alpha-1 antitrypsin deficiency as the cause of COPD
- •Active pulmonary diseases
- •Prior lung volume reduction surgery
- •Abnormal chest X-ray (or CT scan) not due to the presence of COPD
- •Hospitalized due to poorly controlled COPD within 3 months of Screening
- •Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)
- •Cancer that has not been in complete remission for at least 5 years
- •Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives
- •Other inclusion/exclusion criteria as defined in the protocol
Arms & Interventions
PT001 Placebo MDI
Placebo Comparator
Intervention: PT001 Placebo MDI (Drug)
PT001 MDI (Dose 1)
Experimental
Intervention: PT001 MDI (Drug)
PT001 MDI (Dose 2)
Experimental
Intervention: PT001 MDI (Drug)
PT001 MDI (Dose 3)
Experimental
Intervention: PT001 MDI (Drug)
PT001 MDI (Dose 4)
Experimental
Intervention: PT001 MDI (Drug)
PT001 MDI (Dose 5)
Experimental
Intervention: PT001 MDI (Drug)
PT001 MDI (Dose 6)
Experimental
Intervention: PT001 MDI (Drug)
Spiriva® Handihaler® (Tiotropium Bromide)
Active Comparator
Intervention: Tiotropium Bromide (Drug)
Outcomes
Primary Outcomes
FEV1 AUC0-12
Time Frame: Day 14 (-1 hr, -30 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 10 hr, 11.5 hr, 12 hr)
Forced expiratory volume in 1 second (FEV1) normalized area under the curve 0-12 hours (AUC0-12) following chronic dosing for 14 days.
Secondary Outcomes
- Peak Change From Baseline in FEV1(Day 14)
- Time to Onset of Action (>10% Improvement in FEV1) on Day 1(Day 1 (15 min, 30 min, 1 hr, 2 hrs, no onset within 2 hrs))
- Percentage of Subjects Achieving at Least 12% Improvement in FEV1(Day 1)
- Peak Change From Baseline in Inspiratory Capacity (IC)(Day 1 (1 hr and 2 hr post-dose ))
- Change From Baseline in Morning Pre-dose Trough FEV1(Day 14 (average of the 60 and 30-minute pre-dose values on Treatment Day 14 minus the baseline))
- Change From Baseline in Morning Pre-dose Trough Inspiratory Capacity (IC)(Day 7)
- Peak Change From Baseline in IC(Day 14 (mean of 1 and 2 hour post-dose assessments minus the baseline))
- Change From Baseline in Mean Morning Pre-dose Daily PEFR(Baseline, Treatment Day 1 and every day, to the end of the 14-Day Treatment period before dosing, values were averaged for the end of treatment value (all subjects with diary data after Diary day 7))
- Change From Baseline in Morning Post-dose Daily PEFR(Day 7 (30 minutes post-dose))
- Change From Baseline in Mean Evening Pre-dose PEFR(Day 7)
- Change From Baseline in Mean Evening Post-dose PEFR(Day 7)
- Mean Number of Puffs of Rescue Medication(Day 7)
- Change From Baseline for Mean Morning Pre-dose Trough IC(Day 14 (average of the 60 and 30-minute pre-dose assessments minus the baseline))
- Change From Baseline in 12-hour Post-dose Trough FEV1(Day 14 (Baseline, 11.5 and 12 hours post dose))
- Change From Baseline in Mean Morning Post-dose Daily PEFR(Baseline, Treatment Day 1 and every day, to the end of the 14-Day Treatment period 30 minutes post dosing, values were averaged for the end of treatment value (all subjects with diary data after Diary day 7))
- Change From Baseline in Mean Evening Pre-dose Daily PEFR(Treatment Day 1 to the end of the 14-Day Treatment, values were averaged for the end of treatment value (all subjects with diary data after Diary day 7))
- Change From Baseline in Mean Evening Post-dose Daily PEFR(Through the end of the 14-Day Treatment)
- Mean Number of Puffs of Rescue Medication (End of Treatment)(Day 14 (End of treatment))
- Change From Baseline in Morning Pre-dose Trough FEV1 (mL) Averaging Treatment Day 7 and Day 14(Day 1 through Day 14)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT01350128Pearl Therapeutics, Inc.103
Completed
Phase 1
T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerBreast CancerNCT02562378MedSIR15
Completed
Phase 2
PT003 MDI Dose Confirmation StudyChronic Obstructive Pulmonary DiseaseNCT01349816Pearl Therapeutics, Inc.185
Unknown
Phase 1
A Study of Oraxol® in Gastric Cancer PatientsAdvanced Metastatic Gastric CancerRecurrent Gastric CancerNCT01491217Hanmi Pharmaceutical Company Limited53
Terminated
Phase 1
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC PatientsNon-small Cell Lung CancerNCT03064854Novartis Pharmaceuticals111